This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 ...

On Monday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $21.77 which represents a slight increase of $0.36 or 1.68% from the prior close of $21.41. The stock opened at ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

On Thursday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $18.59 which represents a decrease of $-0.06 or -0.32% from the prior close of $18.65. The stock opened at $18.75 and ...

Summit Therapeutics PLC ( (SMMT) ) has realeased its Q3 earnings. Here is a breakdown of the information Summit Therapeutics PLC presented to ...

Summit Therapeutics Inc's innovative approach to combating serious infectious diseases positions it as a potential leader in ...

JMP Securities initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $32 price target The firm acknowledges the risk associated with data obtained from Chinese patients only, ...

GOTHENBURG, SWEDEN / ACCESSWIRE / November 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November ...

Quarterly Cash Burn: Below $35 million for operating activities. Summit Therapeutics Inc (NASDAQ:SMMT) has made significant ...

Complete enrollment in its DMT310 Phase 3 STAR-1 clinical trial in moderate-to-severe acne. Dermata expects to complete enrollment in the STAR-1 study by the end of 2024 and plans to announce topline ...